Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to test the safety and tolerability of the combination
treatment of the investigational drugs vorinostat and pembrolizumab, in combination with
chemotherapy (temozolomide), and radiotherapy. The U.S. Food and Drug Administration (FDA)
has approved pembrolizumab for use to treat a deadly skin cancer called melanoma and lung
cancer and vorinostat to treat some forms of blood and lymph node cancers. However, both
vorinostat and pembrolizumab are considered investigational drugs in this study because they
are not approved for treatment of glioblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute